Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Apple Turns 50: From Garage Startup to AI Crossroads 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
KING OF PRUSSIA, Pa., July 12, 2017 -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will host an Analyst Day on Thursday, July 20, 2017, in New York City. Presentations will begin at 12:00 p.m. EDT and will be simultaneously webcast. The event is expected to conclude by 3:00 p.m.
The presentations will focus on the Company’s clinical portfolio and will feature members of the Trevena management team and leading external experts in acute pain management in the hospital, including:
- Eugene R. Viscusi, M.D. Chief of Pain Medicine, Director of Acute Pain Management, Sidney Kimmel Medical College, Thomas Jefferson University; President-Elect, The American Society of Regional Anesthesia and Pain Medicine,
- Peter Whang, M.D., FACS. Associate Professor, Department of Orthopaedics & Rehabilitation, Yale University School of Medicine,
- Michael H. Bourne, M.D. Orthopaedic Surgeon, Salt Lake Orthopaedic Clinic; Chairman, Division of Orthopaedic Surgery, St. Mark’s Hospital; ATHENA investigator, and
- Hadi Najafian, D.O., FACS, FASCRS. Colon & Rectal Surgeon, West Valley Colon & Rectal Surgery Center.
To join the live audio webcast of the presentation, please visit the Investor section of the Company’s website. Following the conclusion of the presentation, the webcast will be available for replay for 30 days.
About Trevena
Trevena, Inc. is a biopharmaceutical company developing innovative therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The Company’s lead program is OLINVO™ (oliceridine injection), which has completed two successful Phase 3 trials for the management of moderate-to-severe acute pain. Trevena has discovered four novel and differentiated drug candidates, including OLINVO. Trevena also has discovered TRV250, in early clinical development for the treatment of acute migraine. The Company maintains an early stage portfolio of drug discovery programs.
Contacts Trevena, Inc. Investors: Jonathan Violin, Ph.D. Vice President, Corporate Strategy & Investor Relations 610-354-8840 x231 [email protected] or Media: Public Relations [email protected]
